Biomarin projects 2022 Voxzogo sales of USD 115m
US-based Biomarin brought its dwarfism drug Voxzogo to the market in 2021, and the company has great expectations for the drug in 2022.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
US-based biotech firm Biomarin has released its full-year financial report on Wednesday, and in connection with the report came the company’s 2022 sales prognosis for potential cash cow Voxzogo.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin's dwarfism drug receives FDA approval
For subscribers
.jpg&w=384&q=75)
